HAIC for liver cancer: how it differs from TACE and when to discuss it
Hepatic arterial infusion chemotherapy, or HAIC, delivers chemotherapy through an artery supplying the liver. Unlike TACE, HAIC does not depend on adding an embolic step to block the tumor's blood supply. FOLFOX-based HAIC has been studied in selected HCC populations, including large unresectable tumors. Whether it belongs in a treatment plan depends on the disease pattern, liver function, prior treatment and the evidence for the exact regimen being proposed.
On this page
What the treatment is designed to do
HAIC uses the liver's arterial circulation to deliver anticancer medicines. The name describes a route of delivery, so it is important to ask which chemotherapy is included. FOLFOX refers to a combination of fluorouracil, leucovorin and oxaliplatin.
A proposal should explain whether HAIC is the main treatment or part of a broader plan. Ask which disease sites it is intended to control and whether a separate systemic treatment is needed. Cancer outside the liver requires attention in the overall strategy.
How HAIC differs from TACE
TACE adds embolic material to reduce arterial blood flow while delivering chemotherapy. HAIC delivers an infusion without that defining embolization step. They should therefore be compared as different treatment strategies, even though both use an arterial route.
Ask why one is favored for your tumor distribution and liver reserve. If a combined or sequential approach is proposed, have the team explain what each part adds and which response or safety finding would stop the next step.
What the randomized evidence actually studied
A randomized phase III trial compared FOLFOX-HAIC with TACE in adults with unresectable HCC at least 7 cm in its largest diameter, without major vascular invasion or spread outside the liver. The study reported better overall survival and response with HAIC in that selected population.
This is a useful reason to discuss HAIC for a matching case. Patients with major vessel involvement, different liver function or previous systemic treatment raise separate evidence questions. Ask the team which study or guideline best matches your situation.
Sources and references: [1]
Translate the evidence into an individual decision
The assessment needs the current images, liver tests, general fitness and treatment history. Large tumor size alone does not complete the selection. The team also considers whether the liver and other organs can tolerate the proposed chemotherapy.
Ask what result is being sought: control of a large liver burden, a response that might allow another local treatment, or a later option after previous therapy. If future surgery is part of the discussion, the surgical team should define how and when that possibility will be reassessed.
Compare it with today's relevant options
An HAIC discussion should include the systemic therapies and local approaches suitable for the same case. Evidence from a comparison with TACE does not automatically answer how HAIC compares with every immunotherapy-based combination. The prior treatment sequence matters.
Ask why the proposed plan is preferable now, what is known about its combination with other drugs and how additional toxicity will be monitored. If it is offered through a trial, request the study details and the alternatives available outside the trial.
Make the delivery plan concrete
Ask how the arterial access will be managed, how long each infusion lasts and what monitoring is required during and after it. The service should explain whether repeated access or a device is planned and how that affects movement, hospital time and care between cycles.
Request a schedule that includes blood tests and response imaging. Discuss kidney problems, previous chemotherapy reactions and existing numbness or weakness. These details can influence the chemotherapy plan and the support needed to complete it.
Know what would change the next cycle
Treatment review needs both cancer response and tolerability. Ask which blood count or organ-function changes would prompt a delay or modification. Report fever, persistent vomiting, worsening weakness or problems at the access site promptly through the treating service.
If the disease is not responding, ask when the team would stop repeating the regimen and choose another approach. Keep the infusion records and scan images. A clear treatment history will make a later consultation more useful than a statement that arterial chemotherapy was tried.
Preparing an HAIC assessment inquiry
Zhongshan Hospital is a Shanghai liver cancer resource where a treatment comparison can be raised. The receiving service should confirm whether HAIC assessment is relevant and identify the appropriate team for the proposed approach.
EastMedGo can help organize the inquiry with images, liver tests and prior treatment. Include the precise regimen if another hospital has proposed one. We can help clarify consultation arrangements and coordination costs before travel, while the clinical service evaluates the treatment pathway.
Sources and references: [4]
Common questions
Is HAIC another name for TACE?
No. HAIC is an arterial chemotherapy infusion. TACE combines chemotherapy with an embolic step. The treatment plan should specify which approach is proposed.
Does the large-HCC trial prove HAIC is best for portal vein tumor thrombus?
That particular trial excluded major vascular invasion. A patient with tumor thrombus needs a separate assessment and evidence relevant to that disease pattern.
Sources and references: [1]
Sources and references
- Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
- Primary Liver Cancer Treatment (PDQ) – Health Professional Version
- Liver Cancer Treatment
- Zhongshan Hospital Affiliated to Fudan University
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.